288 related articles for article (PubMed ID: 20518075)
1. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease.
Deuter CM; Zierhut M; Möhle A; Vonthein R; Stöbiger N; Kötter I
Arthritis Rheum; 2010 Sep; 62(9):2796-805. PubMed ID: 20518075
[TBL] [Abstract][Full Text] [Related]
2. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
Park JY; Chung YR; Lee K; Song JH; Lee ES
Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
4. [Ocular prognosis in Behçet's disease].
Cochereau-Massin I; Wechsler B; Le Hoang P; Le Thi Huong Du; Girard B; Rousselie F; Godeau P
J Fr Ophtalmol; 1992; 15(5):343-7. PubMed ID: 1430813
[TBL] [Abstract][Full Text] [Related]
5. Results of interferon alpha-2a therapy in patients with Behcet's disease.
Yalçindağ FN; Uzun A
J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B
Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420
[TBL] [Abstract][Full Text] [Related]
8. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
[TBL] [Abstract][Full Text] [Related]
9. Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.
Krause L; Altenburg A; Pleyer U; Köhler AK; Zouboulis CC; Foerster MH
J Rheumatol; 2008 May; 35(5):896-903. PubMed ID: 18412306
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behcet's disease.
Kavandi H; Khabbazi A; Kolahi S; Hajialilo M; Shayan FK; Oliaei M
Clin Rheumatol; 2016 Nov; 35(11):2765-2769. PubMed ID: 27234230
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
13. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].
Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308
[TBL] [Abstract][Full Text] [Related]
14. [The short-term efficacy and safety treatment study of recurrent uveitis in Behcet disease with etanercept].
Zhang MF; Zhao C; Wen X; Du H; Zhao Y
Zhonghua Yan Ke Za Zhi; 2010 Feb; 46(2):145-50. PubMed ID: 20388349
[TBL] [Abstract][Full Text] [Related]
15. Uveitis in Behçet disease: an analysis of 880 patients.
Tugal-Tutkun I; Onal S; Altan-Yaycioglu R; Huseyin Altunbas H; Urgancioglu M
Am J Ophthalmol; 2004 Sep; 138(3):373-80. PubMed ID: 15364218
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
17. [Behçet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients].
Stübiger N; Kötter I; Deuter C; Zierhut M
Klin Monbl Augenheilkd; 2001 Dec; 218(12):768-73. PubMed ID: 11805868
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis.
Deuter CM; Kötter I; Günaydin I; Stübiger N; Doycheva DG; Zierhut M
Br J Ophthalmol; 2009 Jul; 93(7):906-13. PubMed ID: 19321469
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis.
Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S
Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983
[TBL] [Abstract][Full Text] [Related]
20. Uveitis in juvenile Behçet's disease: clinical course and visual outcome compared with adult patients.
Kramer M; Amer R; Mukamel M; Snir M; Jaouni T; Friling R
Eye (Lond); 2009 Nov; 23(11):2034-41. PubMed ID: 19151650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
